Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

MD's stronger cash collections, favorable payer mix, acquisitions and telehybrid care support its growth prospects.

Pediatrix Medical Group’s second quarter was marked by revenue growth exceeding Wall Street’s expectations, but the market responded negatively, reflecting concerns about profitability and underlying operational trends. Management attributed the top-line gains to improved revenue cycle management collections, a favorable payer mix, and rising patient acuity, while acknowledging a modest decline in same-unit patient volumes, particularly in neonatology. CEO Mark Ordan noted, “Same unit revenue wa

Revenue grew 4% despite patient volume declines as pricing gains offset lower utilization.

Why Pediatrix Medical Group’s latest earnings matter for investors Pediatrix Medical Group (MD) recently reported second quarter and first half 2026 results, with higher sales, net income, and earnings per share from continuing operations compared with the same periods a year earlier. See our latest analysis for Pediatrix Medical Group. Pediatrix Medical Group’s earnings update comes after a strong run in the stock, with a 90 day share price return of 15.88% and a year to date share price...

Pediatrix Medical Group, Inc. reported past second-quarter 2026 results with sales of US$487.78 million and net income of US$39.84 million, both higher than a year earlier, alongside slightly improved basic and diluted earnings per share from continuing operations. Over the first half of 2026, the company’s higher sales of US$963.98 million and net income of US$69.42 million indicate that recent operational and cost initiatives are feeding through into stronger earnings per share from...

EHC beats Q2 earnings estimates as higher patient revenues and strong discharge growth drive results, leading the company to raise its 2026 adjusted EPS outlook.

MD posts a Q2 earnings beat as stronger cash collections and a favorable payor mix lift results despite lower volumes.

Pediatrix Medical Group (NYSE:MD) reported second-quarter 2026 adjusted EBITDA of $76 million and reaffirmed its full-year adjusted EBITDA outlook of $280 million to $300 million, as stronger revenue-cycle-management collections, payer mix and patient acuity offset lower patient-service volumes. Ch

Moby summary of Pediatrix Medical Group, Inc.'s Q2 2026 earnings call

Pediatrix Medical Group Inc (MD) reaffirms full-year guidance as pricing gains offset softer neonatology volumes.

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of +10.53% and +2.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 4% year on year to $487.8 million. Its non-GAAP profit of $0.63 per share was 6.6% above analysts’ consensus estimates.

Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) will be reporting earnings this Tuesday before market open. Here’s what to look for.

Bausch + Lomb (BLCO) delivered earnings and revenue surprises of 0.00% and +1.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pediatrix Medical Group has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.3%. The stock now trades at $25.83, marking a 19.9% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Pediatrix Medical Group (MD) drew fresh investor attention after updating second quarter business trends, highlighting a stable payor mix and reaffirming its full year 2026 Adjusted EBITDA outlook of $280 million to $300 million. See our latest analysis for Pediatrix Medical Group. Pediatrix Medical Group’s recent update on stable business trends comes after a strong run, with a year to date share price return of 23.72% and a 1 year total shareholder return of 105.14%. The latest 1 day move...

Pediatrix Medical Group recently reported that its second-quarter 2026 payor mix and other net revenue-related trends remained stable and in line with recent history and internal expectations, while also reaffirming its full-year 2026 Adjusted EBITDA outlook of US$280 million to US$300 million. This confirmation of steady reimbursement patterns and earnings guidance, at a time when many healthcare peers report pressure on payor mix and utilization, highlights Pediatrix’s relatively resilient...

Pediatrix Medical Group (MD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Elevance Health beats Q2 EPS and revenue estimates, raises 2026 adjusted EPS outlook despite lower earnings, softer membership and higher expenses.